All right, we're going to go ahead and get started. I'm Stephen Willey, one of the Senior Biotech Analysts here at Stifel. Very glad to have with us here presenting from Zentalis, CEO Julie Eastland. She's going to provide an overview of the company. We should have some time for Q&A. If anyone has a question, feel free to raise your hand. I'm going to turn it over to Julie. Julie, thank you.
Well, thank you. Thank you as always. We really appreciate the opportunity here at the Stifel conference with such a great audience, and we thank you all for attending and listening to this update on Zentalis and some progress on azenosertib, WEE1 inhibitor that is in development. Before we get started, I just wanted to give you an overview as we think about WEE1. We certainly will be making forward-looking statements with estimates and forecasts, and of course, we direct you to our filings with the SEC for the risks and uncertainties associated with those statements. Maybe just on an overview perspective, I want to make sure that you all understand the strategy and the opportunity that we have been pursuing now, which remains in place, which is to bring azenosertib forward in a monotherapy setting for Cyclin E1 high expressors in the platinum-resistant ovarian cancer setting.
We have been conducting a number of trials in this setting, including the DENALI trial, in particular the Part 2 trial, and the ASPENOVA full phase III randomized control study in the same population, and we'll talk a little bit more about that later. Azenosertib is actually a very well-defined and differentiated asset from other agents that are currently being pursued or approved in this space. Azenosertib is potentially a very first-in-class oral non-chemo, non-ADC therapy, again, for a patient population that is known biologically to have high Cyclin E1 expression, and in particular, in those that we have defined through our IHC assay and our cutoff, those that have high expression in the PROC space, and they typically do worse in earlier lines of therapy and have a poor prognosis.
There's a very high unmet need, and azenosertib offers an opportunity for patients who are coming into the platinum-resistant space to potentially have a break from chemo, be treated for an agent that is directed towards them, and go on to have response rates that are correlated to, again, to their Cyclin E1 high status. We've presented some data at ESMO just last month that continue to expand and provide proof of concept and validation that a biomarker-selected population in this setting is meaningful, and that includes overall survival data that was updated at ESMO for the DENALI Part `1b trial. Again, that's a monotherapy study that was done in all comers earlier. Some of the initial data was presented in 2025 at the SGO conference, and we've updated the response rates, the overall survival, and the duration at the ESMO. We'll go through that in a minute.
We have designed multiple paths to bring azenosertib to market, as I mentioned in the DENALI trial, which could serve for potential accelerated approval, and then in addition to that, the ASPENOVA trial, which is the gold standard phase III randomized control study in the same population. We have always been focused on bringing value to azenosertib beyond monotherapy. Of course, we need proof of concept as a single agent, which we have shown consistently over a number of prior trials, and our strategy is to not only look at ovarian and PROC, but to look at azenosertib in combination with standard of care agents in earlier ovarian, which includes our MUIR trial that we will talk about today, which is currently enrolling azenosertib at a selected combination dose with bevacizumab in the second-line maintenance setting in PSOC.
We announced that we will be looking to also do a combination of azenosertib in the triple-negative breast cancer space based on very compelling preclinical data that we shared at AACR earlier this year. Importantly, we have sufficient financial resources to fund these key objectives. We have reported in Q3 approximately $229 million that will get us through the first half of 2028. That funding helps to achieve key milestones, which includes the readout of the DENALI Part 2 dataset, which we will talk about that patient population in a minute. In addition, the enrollment in ASPENOVA and the development of additional data in these combination studies that I mentioned. This is really outlined here on this slide in terms of our pipeline. As I mentioned, the DENALI trial is a phase II trial. This was a multi-part study. Part 1b has read out and was updated at ESMO.
This was an all-comer population that retrospectively looked at patients with high Cyclin E1 expression. In addition to that, then we have been enrolling the Part 2 of DENALI trial. In this trial, we prospectively screen for patients with Cyclin E1, and then they become eligible to enroll in this trial. So, it is a prospectively identified population. This trial has three parts. We announced earlier this week that we are concluding enrollment in the DENALI trial at the end of the month, and that we will present data in the first half of the year and an outcome on this study, importantly, to serve not only as proof of concept for monotherapy in this patient population in platinum-resistant ovarian cancer, but also the value that this dataset brings in terms of its support of the ASPENOVA controlled phase III trial.
As well as we have mentioned, we believe that we can take this asset into the U.S. market, but we will be looking for a partner to help support the broadening of the value of this asset beyond PROC, and certainly from a global basis. The DENALI dataset is an important part of that dataset to enlist that type of interest. As I mentioned as well, the other trials you see below, which I talked about earlier, are ongoing, and we will provide updates to those as those progress in next year. Coming back just briefly to PROC, because this is an important and actually quite a meaningful segment of the ovarian cancer setting.
Platinum-resistant ovarian cancer worldwide, and that's in the U.S., EU4, U.K., and Japan, and that's a mouthful these days, but PROC represents about 40,000 patients across those geographies, of which approximately half of those patients are predicted to benefit from azenosertib in a platinum-resistant setting for Cyclin E1 high patients. These patients, again, as we mentioned, typically don't do as well. They have nothing but single-agent chemo after having nothing but chemo coming into this setting, and they certainly could use both a directed therapy as well as an opportunity to have a break from chemo.
In addition to that, this market, I think, is well-trodden as you think about the launch of mirvetuximab or ELAHERE, which had a very impressive launch in the first few years, again, with an opportunity for about 35% of this market, and that has generated quite a significant number of sales in the U.S. that you can see here on this slide. So, definitely a meaningful commercial opportunity in PROC for azenosertib, and we look forward to helping these patients. How do we know that we think this is important from our clinical evidence over time? Just briefly here on this slide, you can see that there's a wide body of evidence of clinical data. This drug has been in over 1,000 patients in monotherapy and combination across different tumor types, so it's very well characterized in terms of the dataset that we have for safety and tolerability.
Earlier this year, we announced that we've selected the 400 mg once a day for five days on, two days off schedule of azenosertib in monotherapy in PROC, and that was from our DENALI Part 2a cohort, which was designed to look in a 1-to-1 randomization at the difference between 300 and 400 dose. Also in that population, as you can see, the tolerability and safety here was a profile that was well managed, and importantly, is clinically relevant for patients in a setting where they have IV infusion or surgery as their choices, and here an oral therapy, that again is a non-chemotherapy, is an important part, I think, of the armament for physicians and patients in this population. I want to turn your attention just briefly to the data that was presented and updated. These are the patient characteristics from the DENALI Part 1b.
Again, this was an all-comer population, and what you see here represents all patients in this setting. These were more heavily pre-treated patients with one to five prior lines of therapy, with over 60% of these patients having a median of three prior lines. In addition, the majority of patients had seen bevacizumab, PARP inhibitor, and importantly, about 50% of these patients retrospectively were defined as Cyclin E1 high. Taking a closer look at the activity of the patients who were defined as Cyclin E1 positive, this chart here shows you both activity and a waterfall of the response rates, as well as on the right, the KM curves of the overall survival. On the left, you can see that at ESMO, we slightly updated the overall response here from the prior study, which brought the overall response rate up to 37 for response evaluable.
This included an additional patient post the prior cutoff that had a response. In addition to that, you see the deep and meaningful responses in these patients in this monotherapy at the 400 mg 5/2 dose setting. On the right, you can see the overall survival curves. The top curve is the overall survival for patients that were Cyclin E1 high. This represented about 16 months of overall survival in a population of single-agent chemotherapy that one would expect in an all-comer population to be around 12 months. In addition to that, the bottom curve is in the Cyclin E1 negative patients, where you can see they did not do as well at seven and a half months of overall survival.
Importantly, this data really helps to continue to validate and stress that this biomarker-selected population is a significant population that has responses and meaningful activity and overall survival data here in this PROC population. Turning to tolerability, there was not much update here from the prior study, but importantly, we want to point out a couple things. From the 400 mg doses, you can see here majority of the treatment-related adverse events that we study, which include the hematological treatment-related adverse events, gastrointestinal, and others, in particular fatigue. In the light blue bars, these are grade 1 and 2, or low-grade related events. In the dark blue bar, you see that there are relatively few or low-grade, or low number, low incidence of grade 3 or higher related events.
In the hematological setting, grade 3+ events that relate to neutropenia or thrombocytopenia were in the 11%-12% rate, so quite reasonable, quite looks like most oncology-associated drugs in this space. In addition, in the DENALI 1B trial, we reported out dose interruptions and dose reductions, as well as discontinuation rates. It is important to think about these rates in terms of how much dose intensity do you see of the drug, given interruptions that are short or dose reductions that can be done in increments. Some new data we presented at ESMO last month reported out a dose intensity of over 85% in this population, so quite high, even given the number of short interruptions or reductions that we saw.
We did not report any new grade 5 events over the previously reported two grade 5 events in the DENALI Part 1b trial, and we continue to believe that this dose and this study population can be well supported by the physicians in this setting. I am just going to touch on briefly, I think I have mentioned that the Part 2 of the DENALI trial is completing enrollment. This is a study, as I mentioned, that prospectively screens patients for their Cyclin E1 status. Patients who meet that criteria and who have had one to three prior lines of therapy, or in the case of a folate receptor alpha patient, mirvetuximab, if indicated, could enroll in the trial and receive azenosertib. The first part of this trial was the dose selection.
This was reported out in April of this year with the selection of the 400 mg dose. Then we went on to enroll over 100 patients at that selected dose in part B. The part C that I mentioned included patients who had represented prior taxane-related experience in the PROC setting. Of course, on an integrated basis, patients who have seen either single agent prior taxane, such as paclitaxel, or patients who have seen some of the new agents, the relacorilant combination, or the pembro combination, were enrolled across the trial into these three cohorts. We are concluding part 2C this month, and we expect to have a reasonable population of these patients who have seen prior taxanes across parts A, B, and C, representing about a 30-patient cohort to evaluate these patients to show that the population is representative of patients of approved agents.
We will follow these patients for overall response as the primary endpoint in this phase II study design, with median duration of response and PFS, and of course, safety and tolerability as supportive endpoints in this trial. We will read this out and have a conversation with the agency about the opportunity for accelerated approval for DENALI. We recognize that the landscape of new agents may be shifting next year as we look at ADCs that potentially are coming into their full dataset, and we certainly see this as an opportunity to talk to the agency about a very meaningful and biologically different population that needs new agents that are not served by these new agents coming along, i.e. some of the ADCs. So, we will certainly go and have a conversation with the agency regarding accelerated approval.
We are certainly readying ourselves for potential launch in the U.S., and we will also continue to complete the gold standard phase III control trial of ASPENOVA. We have two shots to win here from a regulatory perspective, and importantly, from a commercial perspective, this agent remains differentiated regardless of those new agents coming to market. Just briefly on the ASPENOVA trial, this is, again, the randomized trial.
It is the same entry criteria here as parts A and B of DENALI Part 2 , and what I mean by that is we prospectively screen patients with Cyclin E1 expression levels if they meet the bar for that based on our IHC assay, and they have had one to three prior lines of therapy, they will be enrolled one-to-one in the treated arm or through investigator's choice, which the gold standard across the globe is single agent chemotherapy, and that will be the control arm in this trial. Primary endpoint, PFS, secondary supportive endpoints, of course, OS and ORR, and of course, tolerability will be followed as well. That study is currently enrolling across many geographical regions. As we bring more sites and more countries up, we will provide an update on our expectations around ASPENOVA and its enrollment at a future date.
This is the study design, just turning to the expansion of the opportunity and value of azenosertib beyond platinum-resistant ovarian cancer. Here we are looking to bring this agent up earlier into ovarian, as I mentioned earlier. Here we are in the second part of the expansion of azenosertib plus bevacizumab. We are currently enrolling this expansion cohort, importantly following this combination for safety and tolerability in this maintenance setting, as well as looking at potential activity of PFS in this known population of patients who have advanced while on a PARP inhibitor in an earlier line and come into the second line maintenance setting where they only have bevacizumab as their option. Here, these patients are known to have roughly a three- to four-month PFS rate, and we certainly would look to see if we can improve upon that in this single-arm combination setting.
If we do, we think that this provides evidence for us to move into the first-line setting as well with this combination. Lastly, we presented some very compelling data at AACR earlier this year. This is preclinical data in the triple-negative setting. On the left-hand side, you see here combinations with TOPO1 ADCs, where we showed enhanced tumor regression in these models of ADC-naive models. Then on the right, you can see post-TOPO1 ADC, the ability to provide additional meaningful responses with MTI payloads post-TOPO1 setting. So, very impressive data, preclinical data, of course, and we are looking to expand this by potentially combining with ADCs in this triple-negative space. We will tell you more about that as that study is designed and begins to be executed in the future. Certainly, we think a very interesting opportunity.
As a WEE1 inhibitor, the combination with standard care agents that drive DNA damage, cell cycle replication stress are important agents that can benefit from the inhibition of WEE1, and there is a very broad opportunity for this agent at combination doses that make sense with agents that have complementary tolerability profiles. We think there is lots of opportunity not only in triple-negative, but in other settings where we see that biological stress cycle happen, for example, in HPV-driven cancers, et cetera. So a lot of opportunity for azenosertib. We just need time and money. To wrap up here briefly, we have a multi-pronged strategy. We certainly are interested in bringing this drug to market as quickly as possible. We have two shots on goal through DENALI, accelerated approval. Should that be open to us, we will pursue that aggressively.
In addition to that, we have the ASPENOVA trial, which is the gold standard phase III control trial that is enrolling and will also provide a market entry in a more global basis for azenosertib. Then, of course, we see compelling clinical data consistently across multiple studies, and most recently with the update of DENALI 1b at ESMO, to continue to support not only the monotherapy setting here, but also to provide validation of this agent in PROC for both DENALI and ASPENOVA. As I mentioned, the franchisable opportunity and the cash and the funding to achieve many of these key milestones over the course of the next year and a half as we bring these agents forward and bring you data next year on DENALI. So, we thank you for your interest. We thank you for your patience.
We thank you for believing that patients in oncology need as many therapies as we can bring them, and this has certainly been shown to be an important therapy that is differentiated. Thank you.
All right. That was great. Thanks, Julie.
Yep.
Maybe just a few questions. The DENALI trial, you are using that as a mechanism to prospectively validate the companion diagnostic.
Yeah.
Correct?
Yes.
When are we going to learn about what that cut value for Cyclin E1 positivity actually is?
Yeah. We've held that confidential because I think we've really been the leaders in looking at Cyclin E1 protein overexpression as opposed to CCNE1 gene amplification. While CCNE1 gene amplification is important and a high percentage of those patients have high Cyclin E1 protein expression, it's not the only driver of protein expression. You really want to look at patients who've had other reasons for the either lack of degradation of the protein or other ways in which it's being driven besides gene amplification. By providing that cutoff, we would really be enabling those other agents that are coming in behind us.
We've kept the cutoff confidential. However, it's very much a straightforward IHC assay with a proprietary antigen, and you look at both staining in terms of the number of cells that are stained as well as intensity. We've provided a number of manuscripts and publications on our IHC assay. We have more coming. At one point, as we think about going into our market building and our pathology awareness, we'll provide that cutoff. We're just not doing that today.
Okay. Have you, out of curiosity, looked at the DENALI phase I-B data that you just presented at ESMO and kind of done that same-
Yes.
-survival analysis, but as a function of gene amplification only and not positivity?
Yes. We haven't presented the OS on that, but we did present the responses.
In fact, on the slide that looked at the curve or the waterfall of responses in the Cyclin E1-positive patients, and in the SGO presentation, it also showed the negative patients. You can see across the bottom, it'll show you where there was gene amplification and not, and whether or not those patients had responses. I think the point there, very important, is that whether or not you have gene amplification, you have a potential to still have high protein expression. So, there were many patients who didn't have gene amplification but still responded and had high protein expression. Some of that detail is in the SGO presentation from 2025. I don't think we've presented and pulled that out on overall survival, but we certainly can consider taking a look at that. It's a good question. Thank you.
I think there was also some translational data that was presented at ESMO suggesting that Cyclin E positivity can be influenced by certain therapies that are received in-
Yeah.
-whether it is Bev, whether it is PARP. As you think about what you are doing in MUIR, for instance, right, where you are going up into platinum-sensitive patients.
Yeah.
Would you expect the representation of Cyclin E positivity to be much different in that patient population relative to what you are seeing-
Right.
-in the PROC patient?
Yeah, I think you may be referring to a study. I know Alexandra Leary presented some data or did a study where she looked at some fresh biopsies and looked at amplification or protein expression over the course of different lines of therapy or in response to different agents. We do not expect to see a significant difference. We do know that it is presumed that chemotherapeutic agents or taxane-related agents may drive some additional cell cycle and maybe even some higher levels of protein expression, but probably not to the point where it really makes a difference between the number of patients that have protein expression hitting the cutoff bar and above. But we do not expect to see that Cyclin E1 protein expression change dramatically over the course of the lines of therapy in PSOC and into PROC.
that it would really change our view of the patient populations that might be available. I think importantly, as we look at that MUIR trial, we will look retrospectively at patients with their protein expression. These patients in this setting is an all-comer population, so we are enrolling all patients in that platinum-sensitive population regardless of their cutoff. But we will retrospectively obviously run that through the assay and determine if there was a difference in their protein expression or a difference in their treatment outcomes in the MUIR trial.
Okay. I know that there were, I think, if I remember correctly, about 15% of patients in the DENALI 1b that had prior mirvetuximab exposure. How are you thinking about that number in the context of DENALI, and do you think prior mirvetuximab exposure, and I am not sure if this has been broken out for DENALI or not, maybe it is interpretable via some of the swim lanes or whatever, but do you think prior mirvetuximab has an impact on what you can then confer from an efficacy perspective? Does that matter?
Well, we haven't seen a difference. We haven't reported that specific data. Of course, when DENALI Part 1b was being enrolled, mirvetuximab was just being approved and was starting to enter into the U.S. market. Of course, it was not available, and I think it's approved in countries within Europe. It's looking for reimbursement.
But at the time of I-B, the agent was just beginning its U.S. market entrance. We would expect to see 20%-25% based on the mirvetuximab sales in the U.S. that eventually that's where the represented market might be. In particular, not all folate receptor alpha patients are high Cyclin E1 patients, so there are some patients who have both, and therefore they become eligible, obviously, for both agents. In DENALI I-B, that 15% probably represented the patient population that was available then. We don't anticipate and we don't see a biological reason why an MTI payload with mirvetuximab would create any kind of resistance-
-to a WEE1 inhibitor after that, and so we don't have any expectations. We have not broken out that data, but not because we have an expectation that we would see something different. Of course, these patients are enrolling in Part 2. Patients who are eligible for mirv, of course, receive mirv, and then they can then receive azenosertib in part two of DENALI.
Okay. How do you think about the advantages of WEE1 inhibition versus CDK2 inhibition in the context of CCNE1 positivity? It was interesting at ESMO, right, I think you were presented back-to-back with the Incyte compound. I think this was maybe kind of part of the discussant. From your lens or your perspective, how would you characterize the advantage of WEE1? I know Incyte has actually deprioritized, right, kind of the PROC effort with their CDK2.
Yeah. That's what we understand.
Yeah.
Yes, at ESMO, Incyte had a rapid oral presentation in the same session that we had an update on the DENALI data, and they had a combination of their agent, their CDK2 agent, along with bevacizumab at that. That was a single arm, 20-something, 24, 23 patients in that combination setting. I'm not sure how to understand that in the PROC setting. However, I can say that CDK2 inhibition, it really hits one of the checkpoints in the cell cycle process. WEE1 is actually a master regulator and can look at both checkpoints in that process, and if there's an escape mechanism in one, then obviously can look to also then create an opportunity to drive additional cell damage and stress to get to mitotic catastrophe in two places.
Cyclin E1 protein expression is really about driving that cell cycle damage and stress that creates the opportunity for us to take the break off the repair mechanism with WEE1 in two places.
to really allow mitotic catastrophe and cell apoptosis. CDK1, or CDK2, excuse me, presents in one of those pathways. There, of course, can be resistant mechanisms around that. I think the advantage of WEE1 is that it provides an opportunity to catch any of that resistance around CDK2 with a second checkpoint.
Okay. I think your comments you made during the presentation would suggest that for the PSOC indication, you would be probably more inclined to try to find a strategic to try to interrogate that. Was that
Well, we certainly hope that the data in the PSOC setting will enable us to go into the first-line maintenance. Those are big studies and long studies.
Yeah.
I think from a partner perspective, we always look for somebody who can bring this drug to patients faster and broader. We do not believe that we would be, in our size company, well-suited to launch globally. From the ASPENOVA trial in the PROC setting, but that there is also an opportunity for a partner to really bring azenosertib beyond that PROC setting by helping to develop in PSOC as well as in these other combination and other tumor types. We think a partner is an important choice-
Yes.
-for us going forward. Whether or not those are regional partners or broader partners really is going to depend on where we are with our asset, what we have interest in, and the DENALI data that will support those conversations.
Okay. Any questions? Julie, thank you very much. Really appreciate it.
Thank you. Thank you, everybody.